IMUX
Immunic·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMUX
Immunic, Inc.
A biotech company that develops and commercializes oral immunotherapies for autoimmune diseases in the US and Europe
1200 Avenue of the Americas, Suite 200 , New York, NY 10036, USA
--
Immunic, Inc., through the acquisition of the assets and business of VitaGen Corporation, commenced operations as a California corporation on May 23, 2003 and changed its name to Vital Life Therapeutics, LLC in June 2003. In January 2004, the company was incorporated again in Delaware. The Company is a biotherapeutic company dedicated to the development of cell-based treatments for acute liver failure. The product candidate is currently in Phase III clinical trials, the ELAD system (or ELAD) is an in vitro bioartificial liver treatment that aims to regenerate a healthy or stable liver from the patient's own liver prior to transplantation. Since its inception, it has basically devoted all its efforts to product development, clinical trials and trial production, and has not realized that the revenue comes from the planned main business.
Company Financials
EPS
IMUX has released its 2025 Q3 earnings. EPS was reported at -0.13, versus the expected -0.18, beating expectations. The chart below visualizes how IMUX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
